Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2018 12:00 ET | Source: Immune Design Corp.

Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab

Overall Response Rate (ORR) of 46% in Patients Receiving the Combination TLR4 Biomarker Continued to Show Higher Response Rate for Patients with High TLR4 Expression (71% ORR) Long-term Follow Up...
November 20, 2018 08:00 ET | Source: Immune Design Corp.

Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...
November 09, 2018 08:00 ET | Source: Immune Design Corp.

Immune Design to Present at Jefferies 2018 London Healthcare Conference

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos...
November 06, 2018 16:01 ET | Source: Immune Design Corp.

Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation...
November 06, 2018 08:01 ET | Source: Immune Design Corp.

Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting

New data further support G100’s broad potential in hematological malignancies and solid tumors SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:...
October 30, 2018 08:00 ET | Source: Immune Design Corp.

Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update

SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it...
October 11, 2018 16:01 ET | Source: Immune Design Corp.

Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305

G100 development to accelerate in follicular lymphoma and beyondCMB305 to be deprioritized to support focus on G100Cash runway extended into 2021Conference call at 2:00 pm Pacific today SEATTLE and...
August 30, 2018 08:00 ET | Source: Immune Design Corp.

Immune Design to Present at Upcoming September Investor Conferences

SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior...
August 01, 2018 16:01 ET | Source: Immune Design Corp.

Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update

G100 advancing to late-stage development following FDA feedbackConference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design...
July 25, 2018 08:00 ET | Source: Immune Design Corp.

Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update

SEATTLE and SOUTH SAN FRANCISCO, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...